Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives. READ MORE
Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.
Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives.
Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse.
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.
Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.
The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.